Millennium Management LLC Sells 135,546 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Millennium Management LLC trimmed its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 80.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,857 shares of the company's stock after selling 135,546 shares during the quarter. Millennium Management LLC's holdings in Compass Therapeutics were worth $49,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its stake in Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after buying an additional 12,917 shares during the period. Independent Advisor Alliance purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $27,000. Mariner LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $30,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $45,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Stock Up 8.7%

Shares of CMPX stock traded up $0.19 on Wednesday, reaching $2.38. The company's stock had a trading volume of 765,396 shares, compared to its average volume of 952,958. Compass Therapeutics, Inc. has a 12-month low of $0.77 and a 12-month high of $4.08. The company has a market capitalization of $329.11 million, a P/E ratio of -5.80 and a beta of 1.41. The stock's 50 day simple moving average is $2.04 and its 200-day simple moving average is $2.20.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.12). Research analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

CMPX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 target price on shares of Compass Therapeutics in a report on Monday, April 21st. Wedbush reissued an "outperform" rating and set a $8.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 1st. Guggenheim reduced their price objective on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a report on Friday, May 9th. D. Boral Capital reissued a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Monday, April 28th. Finally, Leerink Partners upgraded Compass Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $13.13.

Insider Buying and Selling at Compass Therapeutics

In related news, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Anderman bought 20,000 shares of the business's stock in a transaction that occurred on Monday, April 7th. The stock was acquired at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the purchase, the insider now directly owns 21,000 shares of the company's stock, valued at $32,340. The trade was a 2,000.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 29.80% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.